Amarin (AMRN) Stock Forecast & Price Target

$0.60

-0.02 (-3.21%)

(As of 10/2/2024 ET)

Amarin - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 3 Analyst Ratings

Sell
1

Hold
1

Buy
1

Based on 3 Wall Street analysts who have issued ratings for Amarin in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for AMRN.

Consensus Price Target

$1.00
65.56% Upside

According to the 3 analysts' twelve-month price targets for Amarin, the average price target is $1.00. The highest price target for AMRN is $1.00, while the lowest price target for AMRN is $1.00. The average price target represents a forecasted upside of 65.56% from the current price of $0.60.

Get the Latest News and Ratings for AMRN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amarin and its competitors.

AMRN Analyst Ratings Over Time

Type	Current Forecast 10/3/23 to 10/2/24	1 Month Ago 9/3/23 to 9/2/24	3 Months Ago 7/5/23 to 7/4/24	1 Year Ago 10/3/22 to 10/3/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$1.00	$1.00	$1.08	$1.81
Forecasted Upside	65.56% Upside	59.87% Upside	57.83% Upside	112.31% Upside
Consensus Rating	Hold	Hold	Reduce	Hold

Election warning coming true… (Ad)

If you missed it, my emergency election broadcast is now available on replay.

Click here to watch it now.

AMRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amarin Stock vs. The Competition

Type	Amarin	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	61.29% Upside	808.72% Upside	6.89% Upside
News Sentiment Rating	Neutral News See Recent AMRN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Cantor Fitzgerald 3 of 5 stars	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
11/20/2023	JPMorgan Chase & Co. 2 of 5 stars		Reiterated Rating	Underweight
10/25/2023	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$3.00 ➝ $1.00	+31.53%
7/20/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell	$1.50 ➝ $1.00	-7.41%
7/19/2023	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$2.00 ➝ $1.25	-12.59%
10/19/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$3.00 ➝ $2.00	+70.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:34 PM ET.

AMRN Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Amarin is $1.00, with a high forecast of $1.00 and a low forecast of $1.00.
: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There is currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
: According to analysts, Amarin's stock has a predicted upside of 65.56% based on their 12-month stock forecasts.
: Analysts like Amarin less than other "medical" companies. The consensus rating for Amarin is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMRN compares to other companies.